Research
Read how they describe their research on their University of Toronto profile.
Latest papers
Paratonia, Gegenhalten and psychomotor hypertonia Back to the roots.
Schizophrenia research · 2024 · senior author
On the Origins of MAOI Misconceptions: Reaffirming their Role in Melancholic Depression.
Psychopharmacology bulletin · 2023
Appreciating Ladislas Meduna: Visionary Creator of Convulsive Therapy.
The journal of ECT · 2022 · senior author
Latest funding
- $75,000
Regulatory Policy and the Availability of Psychopharmacologic Agents
CIHR · 2008 · Nominated PI
- $83,000
Who will regulate the regulators: the Food and Drug Administration as a wild card in drug development
SSHRC · 2008 · Principal investigator
- $68,904
Culture, diagnosis, and the psychopharmacology of mood disorders, 1950-present
SSHRC · 2003 · Principal investigator
19 publications.
Paratonia, Gegenhalten and psychomotor hypertonia Back to the roots.
Foucher JR, Dormegny-Jeanjean LC, Bartsch AJ, Humbert I, de Billy CC, Obrecht A, Mainberger O, Clauss JME, Waddington JL, Wolf RC, Hirjak D, Morra C, Ungvari G, Schorr B, Berna F, Shorter E
On the Origins of MAOI Misconceptions: Reaffirming their Role in Melancholic Depression.
Van den Eynde V, Parker G, Ruhé HG, Birkenhäger TK, Godet L, Shorter E, Gillman PK
Appreciating Ladislas Meduna: Visionary Creator of Convulsive Therapy.
Fink M, Gazdag G, Shorter E
The notable humanist and scientist Aaron Beck (1921-2021), the revolutionary founder of cognitive therapy.
Mendlowicz MV, Levitan MN, Nardi AE, Shorter E
A historical perspective on illness progression in bipolar disorder.
van der Markt A, Klumpers U, Dols A, Beekman A, Shorter E, Kupka R
The remarkable Juliano Moreira (1872-1933): an Afro-Brazilian psychiatrist, scientist, and humanist in an environment of slavery and racism.
Nardi AE, Carta MG, Shorter E
The first psychiatric pandemic: Encephalitis lethargica, 1917-27.
Shorter E
How amytal changed psychopharmacy: off-label uses of sodium amytal (1920-40).
Gershon A, Shorter E
Electroconvulsive therapy for self-injurious behaviour in autism spectrum disorders: recognizing catatonia is key.
Wachtel LE, Shorter E, Fink M
Hyperthermia for Major Depressive Disorder?
Fink M, Shorter E
Regulatory Policy and the Availability of Psychopharmacologic Agents
Principal investigators: Shorter, Edward
Keywords: Drug Regulation - History; Psychiatric Disorders - Drug Treatment; Psychopharmacology - History
Who will regulate the regulators: the Food and Drug Administration as a wild card in drug development
Principal investigators: Shorter, Edward L.
Keywords: history of psychiatry; history of psychopharmacology; drug development and regulation; regulatory history
Culture, diagnosis, and the psychopharmacology of mood disorders, 1950-present
Principal investigators: Shorter, Edward L.
Keywords: history of psychiatry; history of psychopharmacology; psychiatric diagnosis and classification; drug discovery; drug licensing; mood disorders; depressive disorders; anxiety disorders
From public funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998 with their latest competition results, the Canada Foundation for Innovation, Genome Canada, the Canadian Space Agency, Canada Research Chairs, the Fonds de recherche du Québec, Ontario research funding, Michael Smith Health Research BC, the Canadian Cancer Society, Heart & Stroke and Brain Canada.
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.
Profile data last refreshed on September 29, 2026 from the university directory, publication records and public research funding records.